ALK inhibitor

The FDA ( US Food and Drug Administration ) has approved Tepmetko ( Tepotinib ) for the treatment of adult...


The FDA ( U.S. Food and Drug Administration ) has approved the PD-1 inhibitor Libtayo ( Cemiplimab-rwlc; Cemiplimab ) for...


The FDA ( U.S. Food and Drug Administration ) has approved supplemental New Drug Application ( sNDA ) for Lorbrena...


Preclinical evidence has suggested that Niraparib ( Zejula ), a poly (ADP-ribose) polymerase inhibitor, may synergise with PD-1 inhibitors. Pembrolizumab...


Entrectinib ( Rozlytrek ) is a potent, selective, CNS active, ROS1 tyrosine kinase inhibitor ( TKI ). In a preliminary...


The ALEX study has demonstrated significantly improved progression-free survival ( PFS ) with Alectinib ( Alecensa ) versus Crizotinib (...


The FDA ( U.S. Food and Drug Administration ) has approved Alunbrig ( Brigatinib ) for adult patients with anaplastic...


The European Commission ( EC ) has extended the marketing authorization of Alunbrig ( Brigatinib ) to include use as...


Positive results from the randomized phase 2 ELEKTRA study of Soticlestat in children with Dravet syndrome ( DS ) or...


Opdivo ( Nivolumab ) 3 mg/kg plus Yervoy ( Ipilimumab ) 1 mg/kg ( injections for intravenous use ) was...


The FDA ( U.S. Food and Drug Administration ) has approved Tabrecta ( Capmatinib ) for the treatment of adult...



The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...


NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib ( Rozlytrek ) is a...


Lorlatinib ( Lorviqua ) is a 3rd-generation ALK tyrosine kinase inhibitor ( TKI ) developed to penetrate the central nervous...


Approximately, 95% of patients who have an initial response to ALK tyrosine kinase inhibitors ( ALK-TKIs ) exhibit an incomplete...


The U.S. Food and Drug Administration ( FDA ) has approved Retevmo ( Selpercatinib ) capsules to treat three...


The European Commission has granted conditional marketing authorisation for Rozlytrek ( Entrectinib ) for the treatment of adult and paediatric...


Ensartinib is a novel second-generation ALK tyrosine kinase inhibitor ( TKI ). In phase 1/2 studies, Ensartinib showed promising activity...


The FDA ( Food and Drug Administration ) has granted accelerated approval to Xpovio ( Selinexor ) in combination with...